ABSTRACT
Background Human papillomavirus (HPV) infection is a necessary cause of cervical cancer and is associated with anal, penile, vaginal, and vulvar cancers. Previous studies have suggested a protective effect of male circumcision (MC) on HPV infections in males, and that this protection may be conferred to their female sexual partners. We synthesized the available evidence on the association between MC and HPV infections in males and females.
Methods We performed a systematic review and meta-analysis of the effect of MC on the prevalence, incidence, and clearance of genital HPV infections in heterosexual males and their female sexual partners. We searched multiple databases for studies that assessed MC status and tested for the presence of genital HPV DNA. We used random-effects meta-analysis models to estimate summary measures of effect and 95% confidence intervals (CI) for the prevalence, incidence, and clearance of HPV infections in males and females. We assessed effect modification for prevalence in males using random-effects meta-regression.
Findings We included 32 publications encompassing 25 unique study populations. MC was associated with decreased odds of prevalent HPV infections (odds ratio 0·45, CI 0·34–0·61), a reduced rate of incident HPV infections (incidence rate ratio 0·69, CI 0·57–0·83), and an increased risk of clearing HPV infections (risk ratio 1·44, CI 1·28–1·61) at the glans penis. Effect modification by sampling site was observed for HPV prevalence in males, with greater protection conferred by MC at the glans than the shaft (OR 0·68, 95% CI 0·48–0·98). Females with circumcised sexual partners were at reduced risk for all outcomes.
Interpretation MC protects against various HPV infection outcomes, especially at the glans, and may be a viable prophylactic strategy in regions with a high burden of HPV-associated disease where the HPV vaccine is not commercially available. That the protective effect of MC on HPV infection prevalence varies by penile site has important implications for epidemiologic studies of HPV transmission.
Funding Funded by grant FDN-143347 from the Canadian Institutes of Health Research.
Evidence before this study Previous meta-analyses published in 2011, 2012, and 2017 have assessed the impact of MC on genital HPV infections in males, while systematic reviews published in 2017 and 2019 have described the impact of MC on women’s sexual health outcomes. All meta-analyses of males found a protective effect of MC on HPV prevalence, with inconsistent evidence for the association between MC and HPV incidence and clearance. Systematic reviews in females found a protective effect of MC on HPV prevalence.
Added value of this study We identified an additional 12 publications (including one randomized controlled trial) that were not included in the most recently published systematic review and meta-analysis. We found that in males, MC conferred protection against prevalent HPV infections at the glans and shaft of the penis, protected against the acquisition of HPV infections at the glans, and resulted in increased clearance of HPV infections at the glans and shaft. We also found that MC protected females against various HPV infection outcomes. We considered anatomical site in all analyses and explored effect modification using a meta-regression approach. Our meta-analysis also examined the impact of MC on various HPV infection outcomes in females. To our knowledge, the latter two types of analyses had not been done before.
Implications of all the available evidence Countries with a high burden of HPV-associated diseases, or where the HPV vaccine is not commercially available, may wish to consider male circumcision as a preventive strategy. Both males and their female sexual partners may benefit from MC for protection from HPV infections.
Competing Interest Statement
ELF and MZ hold a patent related to the discovery "DNA methylation markers for early detection of cervical cancer", registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada (October 2018). ELF has served as consultant to Roche, Merck, and BD on HPV diagnostics and prevention. The other authors declare no competing interests.
Funding Statement
Funded by grant FDN-143347 from the Canadian Institutes of Health Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used were from the published studies listed in Table 1 of the manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Joint first authors
Data Availability
All data used in the systematic review, meta-analysis, and meta-regression are available in the supplementary material.
